Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study.
Sakai D, Omori T, Fumita S, Fujita J, Kawabata R, Matsuyama J, Yasui H, Hirao M, Kawase T, Kishi K, Taniguchi Y, Miyazaki Y, Kawada J, Satake H, Miura T, Miyake A, Kurokawa Y, Yamasaki M, Yamada T, Satoh T, Eguchi H, Doki Y.
Sakai D, et al. Among authors: kurokawa y.
Int J Clin Oncol. 2022 Jul;27(7):1154-1163. doi: 10.1007/s10147-022-02162-4. Epub 2022 Apr 30.
Int J Clin Oncol. 2022.
PMID: 35489010
Free PMC article.